Cordiglieri, C., F. Odoardi, B. Zhang, M. Nebel, N. Kawakami, W. E. F. Klinkert, D. Lodygin, F. Luhder, E. Breunig, D. Schild, V. K. Ulaganathan, K. Dornmair, W. Dammermann, B. V. L. Potter, A. H. Guse and A. Flügel: Nicotinic acid adenine dinucleotide phosphate-mediated calcium signalling in effector T cells regulates autoimmunity of the central nervous system. In: Brain 133, 1930-1943 (2010).
Lodygin, D., V. Tarasov, A. Epanchintsev, C. Berking, T. Knyazeva, H. Körner, P. Knyazev, J. Diebold and H. Hermeking: Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. In: Cell Cycle 7, 16, 2591-2600 (2008).
Zhang, W., M. Bauer, R. S. Croner, J. O. W. Pelz, D. Lodygin, H. Hermeking, M. Sturzl, W. Hohenberger and K. E. Matzel: DNA stool test for colorectal cancer: Hypermethylation of the secreted frizzled-related protein-1 gene. In: Diseases of the Colon & Rectum 50, 10, 1618-1626 (2007).
Tarasov, V., P. Jung, B. Verdoodt, D. Lodygin, A. Epanchintsev, A. Menssen, G. Meister and H. Hermeking: Differential regulation of microRNAs by p53 revealed by massively parallel Sequencing - miR-34a is a p53 target that induces apoptosis and G(1)-arrest. In: Cell Cycle 6, 13, 1586-1593 (2007).
Menssen, A., A. Epanchintsev, D. Lodygin, N. Rezaei, P. Jung, B. Verdoodt, J. Diebold and H. Hermeking: c-MYC delays prometaphase by direct transactivation of MAD2 and BubR1. In: Cell Cycle 6, 3, 339-352 (2007).
Lodygin, D. and H. Hermeking: Epigenetic silencing of 14-3-3sigma in cancer. In: Seminars in Cancer Biology 16, 3, 214-224 (2006).
Lodygin, D., A. Epanchintsev, A. Menssen, J. Diebold and H. Hermeking: Functional epigenomics identifies genes frequently silenced in prostate cancer. In: Cancer Research 65, 10, 4218-4227 (2005).
Lodygin, D. and H. Hermeking: The role of epigenetic inactivation of 14-3-3 sigma in human cancer. In: Cell Research 15, 4, 237-246 (2005).
Mhawech, P., A. Benz, C. Cerato, V. Greloz, M. Assaly, J. C. Desmond, H. P. Koeffler, D. Lodygin, H. Hermeking, F. Herrmann and J. Schwaller: Downregulation of 14-3-3 sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation. In: Modern Pathology 18, 3, 340-348 (2005).
Lodygin, D., J. Diebold and H. Hermeking: Prostate cancer is characterized by epigenetic silencing of 14-3-3 sigma expression. In: Oncogene 23, 56, 9034-9041 (2004).
The Max Planck Society does not take any responsibility for the content of this export.